A 5-state CCRAS study has documented significant variations in commercially available Ksheerabala 101 Avarthi preparations, with implications for clinical practice standardisation.
A CCRAS-led pharmaceutical quality study across 5 Indian states has documented significant batch variation in commercially available Ksheerabala 101 Avarthi — the 101-time distilled medicated oil that is among Kerala Ayurveda's most prized preparations.
Findings
The study sampled 30 batches from 12 manufacturers across Kerala, Tamil Nadu, Karnataka, Gujarat, Uttar Pradesh:
Standardisation gap
Ksheerabala 101 Avarthi is widely prescribed for chronic Vata-Pitta disorders (insomnia, headache, anxiety, multiple sclerosis support, cognitive decline). Clinical outcomes depend heavily on preparation authenticity — but until this study, there was no standardised quality reference for the market.
Recommendations from CCRAS
Kerala manufacturers' response
Kottakkal AVS, Vaidyaratnam, and Oushadhi (Kerala govt PSU) have committed to public quality dashboards showing each batch's HPTLC fingerprint. Other manufacturers are evaluating compliance pathway.
Practitioner guidance
Kerala practitioners traditionally source Ksheerabala from established Kerala manufacturers (AVS, Vaidyaratnam). The CCRAS findings reinforce that this source-discipline matters.
Patient guidance
For Ksheerabala 101 Capsule or oil purchase, prioritise:
Full formulation details: /formulary/ksheerabala-101-avarthi
Source: Annals of Ayurvedic Medicine · link